Precision Medicine in Oncology® | Specialty

Chemo + I-O in Frontline mNSCLC: PD-L1 TPS >50%

January 14th 2019

Chemo + I-O in Frontline mNSCLC: PD-L1 TPS 1%-49%

January 14th 2019

Surgery and Locally Advanced NSCLC

January 14th 2019

EGFR and PD-L1 Testing in Locally Advanced NSCLC

January 14th 2019

Durvalumab After CRT in Locally Advanced NSCLC

January 14th 2019

Chemotherapy Considerations in Locally Advanced NSCLC

January 14th 2019

CRT in Locally Advanced NSCLC

January 14th 2019

Targeting Cancer's Achilles Heel: DNA Damage Response Networks Beyond PARP

December 27th 2018

Cancer cells must maintain a delicate balance to prevent catastrophic levels of DNA damage from triggering cell death, and their heavy reliance on the remaining normal DNA damage response components creates a therapeutically targetable Achilles’ heel.

No Easy Answers for Discussing Outcomes With Patients

December 23rd 2018

Maurie Markman, MD, discusses how to address the important issue of survival following a cancer diagnosis.

Dr. Markman on Precision Medicine in Ovarian Cancer

November 30th 2018

Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, and 2018 Giant of Cancer Care for Gynecological Cancers, discusses the impact of precision medicine in ovarian cancer.

Implementing Quality Standards and Personalized Approaches into Oncology

November 30th 2018

Robert D. Orzechowski, MBA, chief operating officer, Lancaster Cancer Center, executive council member, NCODA, discusses the implementation of quality standards and personalized approaches into oncology.

Single Versus Multiagent Therapy: It's Time to Revisit the Choices

November 22nd 2018

Maurie Markman, MD discusses the importance of objective evidence when using a combination approach as opposed to a single-agent treatment.

Dr. Borgen on Precision Medicine in Breast Cancer

November 20th 2018

Patrick Borgen, MD, chair, Department of Surgery, director, Breast Cancer, Maimonides Medical Center, discusses the implementation of precision medicine in breast cancer.

Capivasertib Effective in AKT-Mutated Cancers

November 17th 2018

The investigational AKT inhibitor capivasertib (AZD5363) demonstrated clinical activity in patients with AKT-mutated cancers, suggesting the validity of tailoring treatment to tumor genes.

Methods on Improving Survivorship and Palliative Care

November 17th 2018

Lani Alison, BCN, MS, HCQ, PCMH, CCE, vice president of clinical affairs at Regional Cancer Care Associates (RCCA), discusses future plans to develop an oft-overlooked area of oncology–survivorship/palliative care.

Novel Oral Paclitaxel Formulation Aims to Overcome Drawbacks of IV Version

November 12th 2018

Investigators are assessing whether Oraxol, an oral formulation of paclitaxel, will be safer and more efficacious than the widely used chemotherapy drug administered by traditional intravenous infusion.

New Tools Needed to Manage Toxicities in Modern Era of Cancer Therapy

November 2nd 2018

Maurie Markman, MD, discusses the search for less toxic strategies for the treatment of cancer that may lessen the negative impact on quality of life while maintaining therapeutic efficacy.

Lead IMPACT Investigator Discusses Precision Medicine Across Tumor Types

November 1st 2018

Apostolia-Maria Tsimberidou MD, PhD, discusses the findings from the IMPACT trial and how precision medicine can affect patient care going forward.

The Impact of Precision Medicine in Oncology

October 30th 2018

Ryan Bookout, PharmD, president, Hematology/Oncology Pharmacy Association, clinical pharmacist, Moffitt Cancer Center, discusses the impact of recent advances and precision medicine in oncology.

Improving the Management of EGFR+ NSCLC

October 20th 2018